Neurocrine’s KarXT rival hits in phase 2 schizophrenia trial—but only at lowest dose 28.08.2024 14:55 Fiercebiotech.com Neurocrine’s KarXT rival hits in phase 2 schizophrenia trial—but only at lowest dose ntaylor Wed, 08/28/2024 - 07:55
